UB begins groundbreaking study on 'net effect' on patients of HIV treatments, other drugs

September 03, 2003

BUFFALO, N.Y. -- An antiretroviral drug for HIV, methadone for heroin addiction, a birth control pill and an antidepressant. For some AIDS patients, this is a daily medication regimen. Others take drugs to treat diabetes, opportunistic infections and side effects of antiretrovirals, while still others abuse alcohol, cocaine or heroin.

How do all of these substances affect how HIV drugs work and how do HIV drugs, in turn, affect the other drugs a patient takes?

That question is at the heart of research being conducted by the University at Buffalo's Laboratory for Antiviral Research, where researchers are developing innovative new methods of testing the blood and cells of HIV patients for these interactions.

The work is supported by a new, $2.3 million National Institutes of Health/National Institute for Drug Abuse grant to complete the first major study of complex drug interactions in AIDS patients.

"Fifteen years ago, we were treating people with one basic goal in mind: to prolong their lives," said Gene Morse, Pharm.D., principal investigator, professor and chair of the UB Department of Pharmacy Practice and associate dean of the School of Pharmacy and Pharmaceutical Sciences. "Now we have the drugs to suppress viral replication, but with them come another set of complications. Many of these drugs are interacting and it has been difficult to study all possible interactions during the FDA development process. We want to find out their net effect." The decision to propose a comprehensive study on how antiretroviral drugs interact with other drugs HIV patients take grew out of a recent, multi-year clinical pharmacology study of interactions with methadone by Morse and psychiatrists at New York City's Montefiore Hospital. "A big factor in treating HIV infection are those patients with concurrent substance addiction," explained Morse. "For example, some of the drugs patients take to treat HIV could actually put them into withdrawal from methadone."

UB is the lead institution on the project, conducting laboratory-based studies to measure concentrations of drugs a patient is taking in blood and cells and to analyze the pharmacogenetic basis of different drugs, or how patients' genetic makeup may influence their response to the drugs.

Morse explained that UB is well-positioned to head up the study because its Laboratory for Antiviral Research, an established group of researchers, was formed early in the HIV epidemic to focus on issues on HIV pharmacotherapy.

The lab has aggressively developed innovative methods to analyze quantitatively and qualitatively how multiple antiretroviral drugs and other pharmaceuticals are metabolized in individuals and their effects -- both desirable and undesirable -- on patients.

The UB researchers also will examine complex drug interactions during chronic antiretroviral therapy using pharmacokinetic and pharmacodynamic modeling, the study of how drugs affect the body's systems over time. Pharmacodynamic modeling originated at UB's School of Pharmacy and Pharmaceutical Science in the 1960s and UB has been a major international source of new research in the field ever since.

Alan Forrest, Pharm.D., clinical professor in the UB Department of Pharmacy Practice, heads the Biometrics Study Unit in the department and is a co-investigator on the grant.

During the study, blood samples will be collected from a total of 500 patients enrolled at four clinical sites: Montefiore Hospital in New York City, the University of Rochester, Case Western Reserve University and the University of Miami in Florida. Each site has had prior clinical research collaborations with UB's Laboratory for Antiviral Research.

The study will be conducted and coordinated through the HIV ePharmacotherapy Network, a Web site developed by Morse and his colleagues in 1998 to coordinate HIV clinical pharmacology research. "Considerable variation exists among individuals as to how AIDS drugs are absorbed, distributed and metabolized," he said, "but right now are all prescribed as though 'one size fits all,' according to fixed-dose regimens."

In addition to looking at blood concentrations of drugs and interactions, Morse said the study will examine the levels of multiple drugs that bind to plasma proteins in each patient. "The amount of plasma protein-binding can vary from patient to patient and that can have important clinical implications," said Morse. "For example, the more highly bound to protein the drug is in plasma, then the less there is to get to the tissue sites where HIV can replicate." The study, he added, also is aimed at uncovering some of the long-term toxicities from these drugs, which are becoming an increasing concern because people are living longer with HIV infection.

University at Buffalo

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.